GET DAILY SIGNALSArcus Biosciences (RCUS) Reports Q3 Results with Narrowed Loss Despite -65.4% Revenue Drop
Key Takeaways
- Net loss narrowed to $128 million, or $(1.00) per share, from $135 million, or $(1.27) per share, in the same quarter a year earlier.
- Total revenue fell 65.4% year over year to $9 million, reflecting the wind-down of activities under the Gilead collaboration.
- Research and development (R&D) expenses declined to $117 million from $141 million, driven by streamlining initiatives and the conclusion of domvanalimab-related studies.
- Arcus updated its full-year 2026 GAAP revenue guidance to a range of $70 million to $75 million.
Earnings Context and Why It Matters
Arcus Biosciences is a clinical-stage biopharmaceutical company advancing oncology and immunology programs. Its quarterly results give investors insight into spending discipline and pipeline progress. The third quarter of 2026 was a transitional period as the company wound down late-stage studies for domvanalimab while shifting resources toward casdatifan, its HIF-2α inhibitor for kidney cancer. Revenue tied to collaboration milestones can swing sharply from quarter to quarter, so the report’s most meaningful signals come from cost trends, cash runway, and clinical execution rather than top-line numbers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Arcus reported total revenue of $9 million for the third quarter of 2026, down 65.4% from $26 million in the prior-year period. The decline primarily reflected lower revenue from activities under the Gilead collaboration as those programs wind down or reach completion.
Net loss narrowed to $128 million, or $(1.00) per share (basic and diluted), compared with $135 million, or $(1.27) per share, a year earlier. The loss per share came in modestly wider than the consensus estimate of roughly $(0.89).
Operating expenses continued to trend lower. Research and development (R&D) expenses declined to $117 million from $141 million, while general and administrative (G&A) expenses fell to $23 million from $27 million, reflecting the company’s streamlining efforts. Arcus also updated its full-year 2026 GAAP revenue guidance to a range of $70 million to $75 million.
Market Reaction and Investor Sentiment
Heading into the report, analyst estimates had pointed to a net loss of roughly $(0.89) per share on approximately $8 million in revenue. The reported $(1.00) loss per share came in slightly wider than that consensus, while revenue of $9 million was broadly in line with or modestly above some estimates. For a development-stage biotechnology company, investors tend to weigh pipeline updates and cash position more heavily than quarterly per-share figures, and the narrowing loss alongside declining operating expenses was generally viewed as consistent with the company’s cost-discipline strategy. From what I see, this alignment with expectations on costs stands out as a positive signal.
Forward Outlook and Key Factors to Monitor
Looking ahead, several factors will shape how investors assess RCUS. The company reported cash, cash equivalents, and marketable securities of $694 million as of September 30, 2026, down from roughly $1.0 billion at the end of 2025, and noted that a $288 million October equity financing extends its runway to fund planned operations into 2029.
The most important catalyst remains clinical data for casdatifan, the lead HIF-2α inhibitor being evaluated in clear cell renal cell carcinoma. Additional readouts across the pipeline, including the CD73 inhibitor quemliclustat, will also be closely watched. I’m watching this closely as enrollment pace and data timing could influence sentiment. Investors should monitor whether R&D expenses remain controlled even as spending shifts toward casdatifan, the pace of enrollment in registrational studies, and any updates to collaboration revenue as legacy programs conclude. These dynamics will be central to evaluating both the balance sheet and the long-term clinical value of the portfolio.
Exploring AI Tools for Research
In my view, tools like Tickeron’s AI Screener help streamline the process of comparing clinical-stage biotechs on fundamentals and technical signals. I use it occasionally to cross-check industry peers and spot patterns that might not be obvious from earnings alone, which supports a more disciplined approach to monitoring names like RCUS.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RCUS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 21, 2026
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RCUS's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 218 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 75 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 50-day moving average for RCUS moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for RCUS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.189) is normal, around the industry mean (3.051). P/E Ratio (-4.799) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. RCUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which offers pre-clinical drug discovery and development solutions
Industry Biotechnology
Advertisement